Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008474
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 0
---
Filed Pursuant to Section 424(b)(3)

Registration No. 333-282231

Prospectus Supplement No. 1

(To Prospectus Dated October 29, 2024)

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

395,574 Shares of Common Stock

2,555,246 Pre-Funded Warrants to Purchase up to 2,555,246 Shares of Common Stock

2,950,820 Common Warrants to Purchase up to 2,950,820 Shares of Common Stock

2,555,246 Shares of Common Stock Underlying the Pre-Funded Warrants

2,950,820 Shares of Common Stock Underlying the Common Warrants</div>

This prospectus supplement No. 1 updates, amends and supplements the prospectus dated October 29, 2024 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-282231).

This prospectus supplement is being filed to update, amend and supplement the information in the Prospectus with the information contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2025 (the “Annual Report”), and a consent from the auditor, Forvis Mazars, LLP, to include their audit report from the Annual Report (the “Auditors’ Consent”). Accordingly, we have attached the Annual Report and the Auditors’ Consent to this prospectus supplement.

The Prospectus and this prospectus supplement relate to a reasonable best efforts offering of (i) 395,574 shares (the “Shares”) of common stock, par value $0.00001 per share (“common stock”) and 2,555,246 pre-funded warrants to purchase up to 2,555,246 shares common stock (the “Pre-Funded Warrants”) together with accompanying 2,950,820 common warrants to purchase up to 2,950,820 shares of common stock (the “Common Warrant”). Each share of common stock, or a Pre-Funded Warrant in lieu thereof, is being sold together with an accompanying Common Warrant to purchase one share of common stock.

You should read this prospectus supplement in conjunction with the Prospectus, including any amendments or supplements to it. This